AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2025
Dec 2, 2025
30751_dirs_2025-12-01_8a2d63cf-26b3-4c92-8466-93b2328b6408.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-11-26
Reporting Person: COZADD BRUCE C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-26 | Ordinary Shares | M | 76689 | $123.36 | Acquired | 470021 | Direct |
| 2025-11-26 | Ordinary Shares | M | 811 | $123.36 | Acquired | 470832 | Direct |
| 2025-11-26 | Ordinary Shares | S | 30487 | $178.0617 | Disposed | 440345 | Direct |
| 2025-11-26 | Ordinary Shares | S | 8380 | $179.2295 | Disposed | 431965 | Direct |
| 2025-11-26 | Ordinary Shares | S | 507 | $179.7923 | Disposed | 431458 | Direct |
| 2025-11-26 | Ordinary Shares | S | 38126 | $177.272 | Disposed | 393332 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-26 | Incentive Stock Option (right to buy) | $123.36 | M | 811 | Disposed | 2026-02-24 | Ordinary Shares (811) | Direct |
| 2025-11-26 | Non-Qualified Stock Option (right to buy) | $123.36 | M | 76689 | Disposed | 2026-02-24 | Ordinary Shares (76689) | Direct |
Footnotes
F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $177.70 to $178.685. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $178.72 to $179.705. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $179.73 to $179.96. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.70 to $177.69. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.